Dave Schulte

Dave has more than 15 years of experience, as an investor and investment banker, partnering with entrepreneurs to build innovative health care and technology businesses. He joined Kasier Permanente Ventures in 2003 and helped build KP's investment program. He is now responsible for managing the Fund's investment strategy and day to day activities. Prior to KP Ventures, Dave was a health care and software investment banker at J.P. Morgan, UBS, and Piper Jaffray. He serves or served as a Board Director or Observer for several companies: Atheromed, Baxano (sold to Trans1), Hemosphere (sold to Cryolife) , MetricStream, Nursefinders (sold to Goldman Sachs), Proteus Biomedical, Pulmonx, ValenTx, Valeritas and Xanitos. Dave is a graduate of St. John's University and earned a Master of Public Policy degree from Harvard University.